At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 19, 2026 at 08:00 ET
Taysha Gene Therapies reported financial results for 2025 and provided a corporate update highlighting progress in its TSHA-102 program for Rett syndrome, including dosing in pivotal trials, FDA alignment on BLA-enabling strategies, and a favorable safety profile. Revenue increased to $9.77 million, though net loss widened to $109.0 million due to higher R&D and administrative expenses. The company has $319.8 million in cash, sufficient to fund operations into 2028.
- Revenue increased 17.3% YoY to $9.77 million in 2025
- Net loss widened to $109.0 million in 2025 from $89.3 million in 2024
- R&D expenses rose 30.9% to $86.4 million, driven by clinical trial and manufacturing costs
- Cash and cash equivalents totaled $319.8 million as of December 31, 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access